Antigen-binding molecule comprising altered antibody variable region

Patent metadata

Field	Value
Publication number	US-12509524-B2
Application number	US-201917280239-A
Country	US
Kind code	B2
Filing date	Sep 27, 2019
Priority date	Sep 28, 2018
Publication date	Dec 30, 2025
Grant date	Dec 30, 2025

Abstract

An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.

First claim

The invention claimed is:

1 . An antigen-binding molecule comprising:
(i) a first antigen-binding domain comprising a first heavy chain variable (VH) region, a first heavy chain constant (CH1) region, a first light chain variable (VL) region, and a first light chain constant (CL) region; and (ii) a second antigen-binding domain comprising a second VH region, a second CH1 region, a second VL region, and a second CL region; and (iii) a third antigen-binding domain comprising a third VH region and a third VL region, wherein the antigen-binding molecule further comprises one or more of the following;
at least one bond between an amino acid residue in the first CH1 region and an amino acid residue in the second CH1 region,
at least one bond between an amino acid residue in the first CL region and an amino acid residue in the second CL region,
at least one bond between an amino acid residue in the first CH1 region and an amino acid residue in the second CL region, and
at least one bond between an amino acid residue in the first CL region and an amino acid residue in the second CH1 region;
wherein the first antigen-binding domain is linked to the second antigen-binding domain via an Fc region, a disulfide bond, or a linker, wherein the first antigen-binding domain binds to a first antigen and to a second antigen different from the first antigen, but does not bind to both the first and second antigens at the same time when the first and second antigens are expressed on cell membranes of separate cells, wherein the third antigen-binding domain binds to a third antigen that is different from the first and second antigens; wherein the third antigen-binding domain is linked to one of the following: the first antigen-binding domain, the second antigen-binding domain, or an Fc region; and wherein either (a) or (b) is true;
(a) the second antigen-binding domain binds to the first antigen and to the second antigen, but does not bind to both the first and second antigens at the same time when the first and second antigens are expressed on cell membranes of different cells; or
(b) the second antigen-binding domain binds to either the first antigen or the second antigen, and not to the other.

2 . The antigen-binding molecule of claim 1 , wherein one or both of the first antigen-binding domain and the second antigen binding domain have an alteration, compared to the VH region sequence of SEQ ID NO: 184 and the VL region sequence of SEQ ID NO: 185, of at least one amino acid at a position or positions selected from Kabat numbering positions 31 to 35, 50 to 65, 71 to 74, and 95 to 102 of SEQ ID NO: 184, and Kabat numbering positions 24 to 34, 50 to 56, and 89 to 97 of SEQ ID NO: 185.

3 . The antigen-binding molecule of claim 1 , wherein the first antigen-binding domain and the second antigen-binding domain are linked via an Fc region.

4 . The antigen-binding molecule of claim 3 , wherein the Fc region has reduced binding activity against human Fc gamma R as compared with that of the Fc region of a wild-type human IgG1 antibody.

5 . The antigen-binding molecule of claim 1 , wherein the third antigen-binding domain is linked to either the first antigen-binding domain or the second antigen-binding domain through one of the following linkages:
(A) a link between the C-terminus of a polypeptide comprising the third VH region and the N-terminus of a polypeptide comprising the first or second VH region, (B) a link between the C-terminus of a polypeptide comprising the third VH region and the N-terminus of a polypeptide comprising the first or second VL region, (C) a link between the C-terminus of a polypeptide comprising the third VL region and the N-terminus of a polypeptide comprising the first or second VH region, or (D) a link between the C-terminus of a polypeptide comprising the third VL region and the N-terminus of a polypeptide comprising the first or second VL region.

6 . The antigen-binding molecule of claim 1 ,
wherein the at least one bond is a disulfide bond, wherein the first antigen-binding domain comprises a heavy chain hinge region, wherein the second antigen-binding domain comprises a heavy chain hinge region, and wherein the first antigen-binding domain and the second antigen-binding domain are linked to each other by one or more native disulfide bonds between their respective hinge regions.

7 . The antigen-binding molecule of claim 1 ,
wherein the amino acid residue at EU numbering position 191 in the first CH1 region forms a bond with the amino acid residue at EU numbering position 191 in the second CH1 region.

8 . The antigen-binding molecule of claim 1 , wherein the first antigen is a molecule specifically expressed on a T cell.

9 . The antigen-binding molecule of claim 8 , wherein the second antigen is a molecule expressed on a T cell or any other immune cell.

10 . The antigen-binding molecule of claim 1 , wherein the first antigen is human CD3 and the second antigen is human CD137.

11 . The antigen-binding molecule of claim 1 , wherein the third antigen is a molecule specifically expressed in a cancer cell.

12 . The antigen-binding molecule of claim 10 , wherein the third antigen is a molecule specifically expressed in a cancer cell.

13 . A method for producing an antigen-binding molecule, the method comprising:
(a) providing a host cell containing one or more nucleic acids encoding one or more polypeptides that together form:
(1) a first antigen-binding domain comprising a first VH region, a first CH1 region, a first VL region, and a first CL region;
(2) a second antigen-binding domain comprising a second VH region, a second CH1 region, a second VL region, and a second CL region; and
(3) a third antigen-binding domain comprising a third VH region and a third VL region,
wherein:
(i) each of the first and second antigen-binding domains binds to both a first antigen and a second antigen that is different from the first antigen, but does not bind to both the first and second antigens at the same time when the first and second antigens are expressed on cell membranes of separate cells, or
(ii) the first antigen-binding domain binds to a first antigen and a second antigen that is different from the first antigen, but does not bind to both the first and second antigens at the same time when the first and second antigens are expressed on cell membranes of separate cells, and the second antigen-binding domain binds only to either the first antigen or the second antigen and not to the other;
wherein the third antigen-binding domain binds to a third antigen different from the first and second antigens; (b) culturing the host cell so that the antigen-binding molecule comprising the one or more polypeptides of (a) is produced, wherein the first antigen-binding domain and the second antigen-binding domain of the produced antigen-binding molecule are linked via a first linkage and a second linkage, wherein the first linkage is via an Fc region, a disulfide bond or a linker, and wherein the second linkage is selected from:
at least one bond between an amino acid residue in the first CH1 region and an amino acid residue in the second CH1 region,
at least one bond between an amino acid residue in the first CL region and an amino acid residue in the second CL region,
at least one bond between an amino acid residue in the first CH1 region and an amino acid residue in the second CL region, or
at least one bond between an amino acid residue in the first CL region and an amino acid residue in the second CH1 region; and

optionally, wherein the third antigen-binding domain is linked to any one of

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Igawa Tomoyuki
• Feng Shu
• Ho Shu Wen Samantha
• Shiraiwa Hirotake

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/53

  Hinge · CPC title